Berenberg Downgrades Bristol-Myers Squibb Co. (BMY) to Hold
Get Alerts BMY Hot Sheet
Rating Summary:
6 Buy, 26 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 14 | New: 22
Join SI Premium – FREE
Berenberg downgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Buy to Hold with a price target of $70.00.
Analyst Laura Sutcliffe commented, "One of the key risks to the short-term Buy case for Bristol has crystallised. Following the failure of CheckMate 026 – which evaluated IO drug Opdivo as monotherapy in first-line NSCLC in PD-L1 positive patients – we downgrade our recommendation for Bristol from Buy to Hold. While a lack of success in this particular trial has no impact on about half of Bristol’s IO opportunity, it affects the NSCLC space as a whole, and places Bristol on the back foot in a market where it has, up until now, dominated."
For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.
Shares of Bristol-Myers Squibb Co. closed at $60.58 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho Downgrades Amylyx Pharmaceuticals inc. (AMLX) to Neutral
- China Resources Beer Holdings Co Ltd. (291:HK) (CRHKY) PT Raised to HK$44.67 at Jefferies
- Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio
Create E-mail Alert Related Categories
Analyst Comments, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!